News Column

Studies Conducted at Kinki University on Peptide Vaccines Recently Reported (Clinical Trial of a 7-Peptide Cocktail Vaccine with Oral Chemotherapy...

July 7, 2014



Studies Conducted at Kinki University on Peptide Vaccines Recently Reported (Clinical Trial of a 7-Peptide Cocktail Vaccine with Oral Chemotherapy for Patients with Metastatic Colorectal Cancer)

By a News Reporter-Staff News Editor at Cancer Vaccine Week -- A new study on Biotechnology is now available. According to news reporting out of Osaka, Japan, by NewsRx editors, research stated, "The combination of a peptide vaccine and tegafur-uracil plus leucovorin (UFT/LV) were evaluated in patients with metastatic colorectal cancer refractory to standard chemotherapy. Thirty human leukocyte antigen (HLA)-A2402-positive patients were enrolled in the study."

Our news journalists obtained a quote from the research from Kinki University, "In a cycle of treatment, a vaccine comprising of seven synthetic peptides (five tumor antigen-derived and two vascular endothelial growth factor receptor-derived) was injected weekly, and oral chemotherapy, UFT/LV was given daily for four weeks followed by one week of rest. The immunological and clinical responses were evaluated at the end of every five weeks. Notable adverse events included grade 1 injection site redness/induration in 25 patients. Tumor imaging showed partial response in three patients, stable disease in 15, and progressive disease in 12. Survival analysis indicated that patients who exhibited positive cytotoxic T lymphocyte responses to all seven peptides had longer overall survival compared to other patients."

According to the news editors, the research concluded: "A 7-peptide vaccine used with UFT/LV is safe and is recommended for further trials in patients with metastatic colorectal cancer."

For more information on this research see: Clinical Trial of a 7-Peptide Cocktail Vaccine with Oral Chemotherapy for Patients with Metastatic Colorectal Cancer. Anticancer Research, 2014;34(6):3045-3052. Anticancer Research can be contacted at: Int Inst Anticancer Research, Editorial Office 1ST Km Kapandritiou-Kalamou Rd Kapandriti, PO Box 22, Athens 19014, Greece. (International Institute of Anticancer Research - www.iiar-anticancer.org/; Anticancer Research - www.iiar-anticancer.org/main.php?id=2)

Our news journalists report that additional information may be obtained by contacting K. Okuno, Kinki University, Fac Med, Inst Irnmunotherapy Canc, Osaka 5898511, Japan. Additional authors for this research include F. Sugiura, K. Inoue and Y. Sukegawa (see also Biotechnology).

Keywords for this news article include: Asia, Biotechnology, Osaka, Japan, Drugs, Oncology, Proteins, Colorectal, Proteomics, Vaccination, Chemotherapy, Colon Cancer, Immunization, Cancer Vaccines, Peptide Vaccine, Gastroenterology, Biological Therapy, Biological Products, Clinical Trials and Studies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Vaccine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters